Jazz Pharma (JAZZ) Guides FY12 EPS, Revs Above Views; to Close Azur Pharma Acquisition
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $254.28 +2.24%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (Nasdaq: JAZZ) today provided full year financial guidance for 2012 reflecting the planned business combination with Azur Pharma Public Limited Company, which the companies are targeting to close during the week of January 16, 2012. The company also announced that the Hart-Scott-Rodino waiting period has expired.
In anticipation of the closing of the company's business combination with Azur Pharma, Jazz Pharmaceuticals is providing financial guidance for 2012 as follows:
In anticipation of the closing of the company's business combination with Azur Pharma, Jazz Pharmaceuticals is providing financial guidance for 2012 as follows:
- Revs of $465 - $490 million, versus $462.8 million expected on the Street;
- Product sales of $460 - $485 million; and
- Adjusted EPS of $4.00 - $4.15. The Street sees $3.40
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
- Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
